Jazz Pharmaceuticals is set to unveil its second-quarter earnings tomorrow, following a strong first quarter that delivered $1.07 billion in revenue—up nearly 20% year-over-year—and beat EPS expectations. With analysts projecting 6.7% revenue growth this quarter (up from 2.1% last year) and steady forecasts indicating reliability, Jazz is poised to continue its momentum. Competitors like Bristol-Myers Squibb and Corcept also posted solid growth but with mixed results, driving market interest. Jazz’s stock has risen 2.5% in the past month, trading below its $266.90 average analyst price target—making tomorrow’s report a key moment to see if the company can sustain its upward trajectory.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
